- Home
- BTCT vs TXMD Comparison
BTCT vs TXMD Comparison
Compare BTCT & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BTCT | TXMD |
|---|---|---|
| Founded | 2006 | 2008 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.9M | 24.3M |
| IPO Year | 2019 | 2012 |
Fundamental Metrics
Financial Performance| Metric | BTCT | TXMD |
|---|---|---|
| Price | $1.08 | $2.03 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.7M | 17.3K |
| Earning Date | 11-11-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 73.68 |
| EPS | N/A | ★ 0.02 |
| Revenue | N/A | ★ $1,761,000.00 |
| Revenue This Year | $1.58 | $207.74 |
| Revenue Next Year | N/A | $2.15 |
| P/E Ratio | ★ N/A | $102.00 |
| Revenue Growth | N/A | ★ 35.25 |
| 52 Week Low | $0.43 | $0.99 |
| 52 Week High | $3.12 | $2.95 |
Technical Indicators
Market Signals| Indicator | BTCT | TXMD |
|---|---|---|
| Relative Strength Index (RSI) | 45.00 | 39.02 |
| Support Level | $1.13 | $2.00 |
| Resistance Level | $1.24 | $2.15 |
| Average True Range (ATR) | 0.14 | 0.06 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 12.50 | 0.00 |
Price Performance
Historical ComparisonAbout BTCT BTC Digital Ltd.
BTC Digital Ltd is the ledger technology that underlies bitcoin and other cryptocurrencies, based in the U.S., with a focus on bitcoin mining. A blockchain is a decentralized, distributed, and encrypted digital public ledger that stores information in a secure, verifiable, and permanent way. The company also generates revenue through the resale of mining machines, mining machine rental, and miner hosting services.
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company that owns and manages intellectual property, including trademarks and product rights, which are licensed to third-party pharmaceutical companies. The company generates revenue mainly through royalties and milestone payments from licensed products, including IMVEXXY, BIJUVA, and ANNOVERA, and does not directly manufacture or market pharmaceutical products.